Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02499835 |
Recruitment Status :
Active, not recruiting
First Posted : July 16, 2015
Results First Posted : December 1, 2022
Last Update Posted : December 1, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hormone-Resistant Prostate Cancer Metastatic Malignant Neoplasm in the Bone Metastatic Malignant Neoplasm in the Soft Tissues Metastatic Prostate Carcinoma Prostate Adenocarcinoma Recurrent Prostate Carcinoma Stage IV Prostate Cancer | Biological: Pembrolizumab Biological: pTVG-HP Plasmid DNA Vaccine | Phase 1 Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 66 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Once at least 12 subjects per arm are accrued to Arms 1 and 2, and Arm 3 is open to accrual, accrual will occur only to Arm 3 (other arms will be closed). Extended treatment Arm 4 will open only when Arm 3 has met accrual. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer |
Actual Study Start Date : | July 1, 2015 |
Actual Primary Completion Date : | August 9, 2021 |
Estimated Study Completion Date : | June 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm I (pTVG-HP plasmid DNA vaccine, concurrent pembrolizumab)
Patients receive pTVG-HP plasmid DNA vaccine ID every other week on days 1, 15, 29, 43, 57, and 71 and pembrolizumab IV over 30 minutes every 3 weeks on days 1, 22, 43, and 64.
|
Biological: Pembrolizumab
Given IV
Other Names:
Biological: pTVG-HP Plasmid DNA Vaccine Given ID |
Experimental: Arm II (pTVG-HP plasmid DNA vaccine, sequential pembrolizumab)
Patients receive pTVG-HP plasmid DNA vaccine ID as in Arm I and pembrolizumab IV over 30 minutes every 3 weeks on days 85, 106, 127, and 148.
|
Biological: Pembrolizumab
Given IV
Other Names:
Biological: pTVG-HP Plasmid DNA Vaccine Given ID |
Experimental: Extended Treatment Arm III
pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
|
Biological: Pembrolizumab
Given IV
Other Names:
Biological: pTVG-HP Plasmid DNA Vaccine Given ID |
Experimental: Extended Treatment Arm IV
pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) every 2 weeks, for a maximum of 24 doses Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 4 weeks, for a maximum of 12 doses, beginning on day 1 after the first pTVG-HP vaccination
|
Biological: Pembrolizumab
Given IV
Other Names:
Biological: pTVG-HP Plasmid DNA Vaccine Given ID |
- Incidence of Adverse Events, Using the National Cancer Common Terminology Criteria, Version 4 [ Time Frame: Up to 23 months (Up to 12 months after completion of study treatment) ]Toxicities will be summarized by type, as reported in the adverse events section, and total events calculated per arm.
- 6-month Progression Free Survival Rate [ Time Frame: 6 months ]6-month progression-free survival rate will be reported for each arm, and for overall combined study. Progression is at least a 20% increase in the sum of diameters of target lesions and a 0.5cm minimum increase, or the appearance of one or more new lesions. In order to evaluate the 6-month progression-free rate as a function of baseline time point (pretreatment or 3-months post treatment), analysis will be conducted using two different baseline values: date of randomization, and 3-months disease assessment. Central tendency is appropriate due to 20% increase and measurements being a mean of growth across time periods.
- Median Time to Radiographic Progression [ Time Frame: Up to 2 years ]Median time to radiographic progression will be estimated for each, and for both study arms combined, using Kaplan-Meier method. Log-rank test will be used to perform comparison of time to radiographic progression between study arms. A one-sided 0.10 significance level will be used to conduct the comparison of the 6-month progression-free survival rate and time to radiographic progression between study arms. In order to evaluate the median time to radiographic progression as a function of baseline time point (pretreatment or 3-months post treatment), analysis will be conducted.
- Number of Participants Who Have an Objective Response [ Time Frame: Up to 2 years ]Will be calculated for each study arm and for all arms combined. Complete response is the disappearance of all target lesions. Partial response is at least 30% decrease in the sum of diameters of target lesions.
- Number of Participants Who Have a PSA Response [ Time Frame: Up to 2 years ]Will be calculated for each study arm and for all arms combined. PSA complete response is a decrease in PSA to ,0.2 ng/mL; partial response is greater than or equal to 50% reduction in baseline PSA.
- PAP-specific Immune Response [ Time Frame: Up to 2 years ]Number of PAP-specific immune responses will be summarized in tabular format for each study arm and all study arms combined. A significant antigen-specific response resulting from immunization will be defined as a PAP specific response.
- PAP-specific T-cell Response [ Time Frame: Up to 2 years ]Number and frequencies of PAP-specific T-cell responses will be summarized in tabular format.
- PD-1 Expression [ Time Frame: Up to day 85 ]PD-1 and PD-L1 expression levels will be summarized in terms of means, standard deviations and ranges for each study arm separately and for both arms combined. A linear regression model or a negative binomial regression model will be utilized to evaluate effects of schedule (concurrent versus delayed administration pembrolizumab) on PD-1 expression on number of circulating T cells, and PD-L1 expression on number of circulating epithelial cells. Choice of the model will be dependent on distribution of outcome variables (number of circulating T-cells and number of circulating epithelial cells).
- PD-L1 Expression [ Time Frame: Up to day 85 ]PD-1 and PD-L1 expression levels will be summarized in terms of means, standard deviations and ranges for each study arm separately and for both arms combined. A linear regression model or a negative binomial regression model will be utilized to evaluate effects of schedule (concurrent versus delayed administration pembrolizumab) on PD-1 expression on number of circulating T cells, and PD-L1 expression on number of circulating epithelial cells. Choice of the model will be dependent on distribution of outcome variables (number of circulating T-cells and number of circulating epithelial cells).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
- Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT of abdomen/pelvis, bone scintigraphy)
-
Castrate-resistant disease, defined as follows:
- All patients must have received (and be receiving) standard of care androgen deprivation treatment (surgical castration versus gonadotropin-releasing hormone [GnRH] analogue or antagonist treatment); subjects receiving GnRH analogue or antagonist must continue this treatment throughout the time on this study
- Patients may or may not have been treated previously with a nonsteroidal antiandrogen; for patients previously treated with an antiandrogen, they must be off use of anti-androgen for at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to registration; moreover, subjects who demonstrate an anti-androgen withdrawal response, defined as a >= 25% decline in PSA within 4-6 week of stopping a nonsteroidal antiandrogen, are not eligible until the PSA rises above the nadir observed after antiandrogen withdrawal
- Patients must have a castrate serum level of testosterone (< 50 ng/dL) within 6 weeks of day 1
-
Progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) bone scan criteria or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during or after completing last therapy:
- PSA: at least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, with the final value >= 2.0 ng/mL
- Measurable disease: >= 50% increase in the sum of the cross products of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be at least 15 mm by spiral CT to be considered a target lesion
- Non-measurable (bone) disease: the appearance of two or more new areas of uptake on bone scan (or fluorine F 18 sodium fluoride [NaF] PET/CT) consistent with metastatic disease compared to previous imaging during castration therapy; the increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (e.g. X-ray, CT or magnetic resonance imaging [MRI])
- Prior treatment with abiraterone or enzalutamide is permitted, but patients must have been off prior corticosteroid treatment for at least 3 months
- Life expectancy of at least 6 months
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- White blood cells (WBC) >= 2000/mm^3
- Absolute neutrophil count (ANC) >= 1000/mm^3
- Hemoglobin (HgB) >= 9.0 gm/dL
- Platelets >= 100,000/mm^3
- Creatinine =< 2.0 mg/dL
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
- No known history of human immunodeficiency virus (HIV) 1 and 2, human T-lymphotropic virus (HTLV)-1, or active hepatitis B or hepatitis C
- Patients must be at least 4 weeks from any prior treatments and have recovered (to < grade 2) from acute toxicity attributed to this prior treatment, unless considered chronic
- Patients must be willing and able (in the opinion of the treating physician) to undergo two research biopsies for the investigational component of this trial
- Patients must be willing to undergo two leukapheresis procedures for the investigational component of this trial
- Patients must be willing to undergo FLT PET/CT or NaF PET/CT scans for the investigational component of this trial and have no known allergies to FLT or NaF
- For those patients who are sexually active, they must be willing to use barrier contraceptive methods during the period of treatment on this trial (and for four weeks after the last DNA immunization treatment for patients in Arm 1)
- Patients must be informed of the experimental nature of the study and its potential risks, and must sign an Institutional Review Board (IRB)-approved written informed consent form indicating such an understanding
Exclusion Criteria:
- Small cell or other variant (non-adenocarcinoma) prostate cancer histology, unless there is evidence that the tumor expresses PAP
- Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy
- Concurrent bisphosphonate therapy is not excluded, however patients should not start bisphosphonate therapy while on this study; those patients already receiving bisphosphonate therapy should continue at the same dosing and schedule as prior to study entry
- Rapidly progressive symptomatic metastatic disease, as defined by the need for increased opioid analgesics within one month of registration for the treatment of pain attributed to a prostate cancer metastatic lesion; patients receiving opioids must receive approval from the principal investigator (PI) for eligibility
-
Treatment with any of the following medications within 28 days of registration, or while on study, is prohibited:
- Systemic corticosteroids (at doses over the equivalent of 5 mg prednisone daily) - not permitted within 3 months of registration; inhaled, intranasal or topical corticosteroids are acceptable
- Prostate cancer (PC)-SPES
- Saw palmetto
- Megestrol
- Ketoconazole
- 5-alpha-reductase inhibitors - patients already taking 5-alpha-reductase inhibitors prior to 28 days prior to registration may stay on these agents throughout the course of therapy, but these should not be started while patients are on study
- Diethyl stilbestrol
- Abiraterone
- Enzalutamide
- Radium 223 (Xofigo)
- Any other hormonal agent or supplement being used with the intent of cancer treatment
- External beam radiation therapy within 4 weeks of registration is prohibited, or anticipated need for radiation therapy (e.g. imminent pathological fracture or spinal cord compression) within 3 months of registration
- Major surgery within 4 weeks of registration is prohibited
- Prior cytotoxic chemotherapy (for example, but not limited to, docetaxel, mitoxantrone, cabazitaxel) within 6 months of registration is prohibited
- Patients with a history of life-threatening autoimmune disease
- Patients with a history of allergic reactions to filgrastim (GM-CSF) or the tetanus vaccine
- Patients who have undergone splenectomy
- Patients must not have other active malignancies other than non-melanoma skin cancers or superficial bladder cancer; subjects with a history of other cancers who have been adequately treated and have been recurrence-free for >= 3 years are eligible
- Patients with known brain metastases
- Any antibiotic therapy or evidence of infection within 1 week of registration
- Any other medical intervention or condition, which, in the opinion of the PI or treating physician, could compromise patient safety or adherence with the study requirements (including biopsies or leukapheresis procedures) over the primary 3-6 month treatment period
- Patients cannot have concurrent enrollment on other phase I, II, or III investigational treatment studies
NOTE: There is no exclusion for prior immune-based therapy. This includes patients previously treated on Arms 1 or 2 who are otherwise eligible for treatment on Arm 3 or 4.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02499835
United States, Wisconsin | |
University of Wisconsin Carbone Cancer Center | |
Madison, Wisconsin, United States, 53792 |
Principal Investigator: | Douglas G McNeel, MD PhD | University of Wisconsin, Madison |
Documents provided by University of Wisconsin, Madison:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT02499835 |
Other Study ID Numbers: |
UW15014 2015-0453 ( Other Identifier: IRB ) NCI-2015-01154 ( Registry Identifier: NCI CTRP ) A534260 ( Other Identifier: UW Madison ) SMPH\MEDICINE\HEM-ONC ( Other Identifier: UW Madison ) Protocol Version 3/19/2018 ( Other Identifier: UW Madison ) |
First Posted: | July 16, 2015 Key Record Dates |
Results First Posted: | December 1, 2022 |
Last Update Posted: | December 1, 2022 |
Last Verified: | November 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Prostatic Neoplasms Neoplasms Neoplasms, Second Primary Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Prostatic Diseases Pembrolizumab Immunoglobulins Immunoglobulin G Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs |